Prognostic Impact of Repeated NT-proBNP Measurements in Patients With Heart Failure With Reduced Ejection Fraction (JACC Heart Failure March 2024)-Article: Prognostic Impact of Repeated NT-proBNP Measurements in Patients With Heart Failure With Reduced Ejection Fraction

Article: Prognostic Impact of Repeated NT-proBNP Measurements in Patients With Heart Failure With Reduced Ejection Fraction

Back to course

Pdf Summary

Repeated measurements of N-terminal pro–B-type natriuretic peptide (NT-proBNP) are a stronger predictor of outcomes in heart failure with reduced ejection fraction (HFrEF) compared to single measurements alone, according to a study published in the Journal of the American College of Cardiology: Heart Failure. The study analyzed data from the GUIDE-IT trial, which enrolled 894 patients with chronic HFrEF and measured NT-proBNP levels over a 2-year period. The results showed that each doubling of the baseline NT-proBNP level was associated with a higher risk of cardiovascular death or heart failure hospitalization. Serial measurements of NT-proBNP increased the adjusted risk even further. In addition, the study found that changes in NT-proBNP occurred weeks before the onset of adverse events. The findings suggest that routine monitoring of NT-proBNP could assist in clinical decision-making and help identify patients at risk for decompensation. However, it is important to note that the study was observational and the results cannot establish causality. Further research is needed to validate these findings in larger trials and examine the impact of serial NT-proBNP monitoring on outcomes in heart failure patients.

Keywords

N-terminal pro–B-type natriuretic peptide

NT-proBNP

heart failure with reduced ejection fraction

HFrEF

GUIDE-IT trial

cardiovascular death

heart failure hospitalization

serial measurements

clinical decision-making

decompensation